We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Selenium Supplementation of Patients With Cirrhosis

This study has been terminated.
(Insufficient funds to complete study.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00271245
First Posted: December 30, 2005
Last Update Posted: March 7, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
RBurk, Vanderbilt University
  Purpose
The purpose of this study is to determine whether patients with liver cirrhosis can improve their selenium nutritional status by taking supplemental selenium.

Condition Intervention
Liver Disease Dietary Supplement: 200 µg selenium as selenate Dietary Supplement: 400 µg selenium as selenate Dietary Supplement: 200 µg selenium as selenomethionine Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Selenium Supplementation of Patients With Cirrhosis

Resource links provided by NLM:


Further study details as provided by RBurk, Vanderbilt University:

Primary Outcome Measures:
  • Plasma selenoprotein P, Plasma GPX-3 activity, Total plasma selenium [ Time Frame: 8 week ]

Enrollment: 99
Study Start Date: February 2006
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
200 µg selenium as selenate
Dietary Supplement: 200 µg selenium as selenate
200 µg selenium as selenate
Experimental: 2
400 µg selenium as selenate
Dietary Supplement: 400 µg selenium as selenate
400 µg selenium as selenate
Experimental: 3
200 µg selenium as selenomethionine
Dietary Supplement: 200 µg selenium as selenomethionine
200 µg selenium as selenomethionine
Placebo Comparator: 4
placebo
Dietary Supplement: Placebo
Placebo

Detailed Description:

Selenium is an essential nutrient. Selenium carries out its biological functions through selenoproteins. The liver converts dietary selenium to a form that can be used to make selenoproteins. Patients with cirrhosis have much lower selenium levels than healthy individuals. We hypothesize that patients with cirrhosis are unable to utilize dietary selenium for selenoprotein synthesis. These patients may benefit from another form of selenium: selenate.

We will compare the effects of two supplemental forms of selenium on plasma selenium levels in patients with cirrhosis. Patients will be randomized to receive either a placebo, 200 µg selenomethionine, 200 µg selenate or 400 µg selenate, daily, for 8 weeks. We will measure selenium levels in the blood at baseline, week 4 and week 8. We will determine which forms of selenium, if any, increased plasma selenium levels of the cirrhosis patients.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • liver disease
  • aged 18 or above

Exclusion Criteria:

  • substance abuse
  • renal failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00271245


Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Raymond F Burk, M.D. Vanderbilt University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: RBurk, M.D., Vanderbilt University
ClinicalTrials.gov Identifier: NCT00271245     History of Changes
Other Study ID Numbers: DK58763-c
R01DK058763 ( U.S. NIH Grant/Contract )
DK58763
First Submitted: December 29, 2005
First Posted: December 30, 2005
Last Update Posted: March 7, 2012
Last Verified: March 2012

Keywords provided by RBurk, Vanderbilt University:
cirrhosis
liver disease
selenium
selenoproteins
selenoprotein P
biomarkers

Additional relevant MeSH terms:
Fibrosis
Liver Cirrhosis
Liver Diseases
Pathologic Processes
Digestive System Diseases
Selenium
Selenic Acid
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Trace Elements
Micronutrients
Growth Substances